Efficacy and safety of valsartan 160/HCTZ 25 mg in fixed combination in hypertensive patients not controlled by candesartan 32 mg plus HCTZ 25 mg in free combination
Authors:
- 12 September 2007
- journal article
- clinical trial
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 23 (11) , 2877-2885
Abstract
Objective: Free combination hypertension medication is associated with a lower compliance and less persistence compared to fixed combination therapy and can, therefore, be associated with insufficient blood pressure reductions. This non-randomized study investigated whether valsartan 160 mg/ hydrochlorothiazide 25 mg (Val 160/HCTZ 25) in fixed dose combination could provide additional blood pressure control in hypertensive patients not adequately controlled by the free combination of candesartan 32 mg plus HCTZ 25 mg. Research design and methods: One hundred and ninety-seven patients with a mean sitting diastolic blood pressure (MSDBP) between 100 and 110 mmHg entered a 4-week treatment phase with 32 mg of candesartan in free combination with 25 mg of HCTZ once daily. One hundred and thirty-eight patients with uncontrolled BP at Week 4, entered a second 4-week treatment phase with Val160/ HCTZ 25 once daily. Main outcome measures: The primary efficacy parameter was the reduction in MSDBP at trough between Week 4 and Week 8 in the intent-to-treat population. Results: At baseline, MSDBP was 103.0 ± 2.8 mmHg. After Week 4, MSDBP had decreased to 93.8 ± 4.5 mmHg. Subsequent treatment with Val 160/HCTZ 25 for 4 weeks reduced MSDBP to 88.7 ± 8.6 mmHg. This represented an additional decrease in MSDBP of 5.1 ± 7.9 mmHg ( p < 0.0001). Val 160/ HCTZ 25 reduced mean sitting systolic BP by 3.4 ± 13.0 mmHg ( p = 0.0029). Conclusions: The fixed dose combination of valsartan 160/HCTZ 25 mg provided a statistically and clinically significant additional BP reduction in patients not controlled by the free combination of candesartan 32 mg and HCTZ 25 mg.Keywords
This publication has 13 references indexed in Scilit:
- Persistence, Adherence, and Risk of Discontinuation Associated with Commonly Prescribed Antihypertensive Drug MonotherapiesThe Journal of the American Board of Family Medicine, 2007
- Recommendations for Blood Pressure Measurement in Humans and Experimental AnimalsHypertension, 2005
- Global burden of hypertension: analysis of worldwide dataThe Lancet, 2005
- Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE TrialThe Lancet, 2004
- Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialThe Lancet, 2004
- Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuriaJournal of the Renin-Angiotensin-Aldosterone System, 2004
- Hypertension Treatment and Control in Five European Countries, Canada, and the United StatesHypertension, 2004
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 ReportJAMA, 2003
- Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesThe Lancet, 2002
- Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trialThe Lancet, 1998